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Abstract
Objective
Proprietary intermediate telehealth devices are those which are specifically designed
as connectors between the entities of telehealth systems. This paper seeks to
understand what are the capabilities of such devices and then to investigate how
these are clustered on the current generation of devices.
Materials and Methods
14 current-generation devices available from 12 device providers were selected and
analysed. Four categories of questions were composed to evaluate the devices:
setup/configuration, available features, inputs and outputs.
Results
Data was collected and synthesised on the following capabilities: availability from
suppliers, setup, environments of use, multiple-condition monitoring, multiuser
capabilities, prompts, reminders and alerts, interaction with the health professional,
access to historical data, device inputs and their transfer technology.
Conclusions
There are three main roles for proprietary intermediate devices in telehealth
systems: displaying information to the patient; receiving data
manually/automatically; forwarding results and questionnaire responses to another
entity.
Provider perspective: Intermediate devices are usually part of closed proprietary
systems. Providers produce disease-customisable devices. Connectivity is
considerably ahead of the current generation of point-of-care devices. However,
little data is available on connection to rest of the proprietary system.
Patient perspective: Clear benefit that one intermediate device can potentially be
used with several chronic conditions. Simple setup, authentication procedures and
automatic data transfer are key design aspects.
Health Professional perspective: Little direct interaction with the health professional.
Payer perspective: Details of costs of devices are generally unavailable; system
providers indicate cost variability is based on “user requirements”.
21 Introduction
Intermediate telehealth devices can be defined as connectors between entities of
telehealth systems [1].
They fall into two classes. The first class is adapted devices which are those originally
designed for other uses and have been adapted for telehealth systems, usually via
integrating software into the device. These include mobile phones and personal
computers (PC). The second class is proprietary devices, which, in contrast are those
specifically designed for use in a telehealth system [1].
From a systems perspective, there is evidence that intermediate devices are the key
invariant component in a telehealth system. A particular telehealth offering can be
used for multiple diseases, and contain varied types of actors, but its intermediate
device or devices are usually fixed: possessing particular sets of capabilities [1]. For
this reason their capabilities form an important area of study.
1.1 Previous case studies
Some descriptions of the use of individual intermediate devices already exist in the
literature. For example, Luptak et al., describe a study in which patient feedback was
obtained on intermediate device used in daily chronic care [2].
Case-study evidence is also emerging that such devices can form part of systems that
have tangible medical impact. Several PCTs (Primary Care Trusts) within the UK, have
implemented telehealth systems incorporating intermediate devices. Examples
include systems for patients with heart failure, and devices in systems to monitor
chronic obstructive pulmonary disease (COPD) [3]. Device use in the latter has
helped community nurses to prioritise their work, resulting in a decrease by 80% of
home visits [3].
1.2 The perspective of healthcare providers
However, there has been no systematic study of the capabilities of current
intermediate devices, nor of how those capabilities are clustered on current devices.
From the perspective of those considering implementing telehealth systems for
chronic care, this means that it is difficult to know whether their expectations could
be met with current systems. For example, the answer to a question such as, can
current telehealth systems monitor multiple diseases and if so what range of
diseases can be covered, is dependent on whether the intermediate device of a
system will connect with and process data from multiple point-of-care devices.
Questions on how patients are monitored, prompted and advised are also
dependant on the capabilities of intermediate devices. The same is true for
questions of data security and confidentiality, key information capture and system
usability.
1.3 Research questions
This paper assesses currently available intermediate devices in telehealth systems.
3It initially seeks to do two things. Firstly, to understand the capabilities of such
devices. Secondly, to show how such capabilities are clustered on the current
generation of devices.
Using this information it then seeks to summarise the capabilities of the devices as
seen from an actor-centric viewpoint, i.e. the viewpoint of a potential patient,
caregiver, health professional or payer.
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2.1 Criteria for selecting devices
As little information is currently available on adapted devices, this study was limited
to proprietary devices. It was also limited to devices which met the following criteria:
1. Devices that have a degree of certification i.e. FDA 510(k) or CE mark.
2. Devices that have been designed primarily for a patient rather than a health
professional.
3. Devices that can be used outside the hospital environment.
Using these criteria, a total of 14 intermediate devices were analysed. Table 1 lists
the devices evaluated, the organization using or distributing them, the type of
certification and appropriate references.
2.2 Data capture
Proprietary devices available between November 2009 and April 2010 were
analysed. Company websites and brochures were assessed to obtain information
about the proprietary devices. Where there were insufficient details, the
organizations were contacted requesting additional information and where
necessary, a visit to the organisation was made.
5Organization Device name Certifications References
AxSys Technology
Ltd
Exceliview (no
longer supported)
Could not be obtained AxSys [4]
Bosch/Health Hero
Network
Health Buddy CE compliant; TUV US
& C medical approved;
FDA 510(k)
Health Hero Network
[5];
FDA [6]
Cardiocom Commander Home
monitor
FDA 510(k) FDA [7]
CareFusion TeleAM CE Mark; FDA Personal
communication,
Jürgen Behringer [8]
Docobo HealthHUB ISO 9002/EN46002 and
European Class IIa
Medical Device
standards
Carson et al., [9];
Docobo [10]
DigiO2 Care Pal FDA 510(k) DigiO2 [11 - 12];
FDA [13]
Honeywell
International Inc/
Home Telehealth
Ltd
Honeywell
HomMed Genesis
DM
FDA 510(k) Honeywell [14];
Home Telehealth Ltd
[15];
Advantage
HomeHealth Services
[16];
FDA [17]
Intel Health Guide FDA 510(k) Intel [18 - 19]
MedApps HealthPAL FDA 510(k) FDA [20]
Telehealth
solutions
Home pod Could not be obtained Telehealth Solutions
[21 - 22]
Tunstall mymedic
Telehealth Monitor
CE Marked; Medical
Device directive
Tunstall [23 -26]
mymedic plus
Telehealth Monitor
FDA 510(k) Tunstall [23 – 24],
[26];
FDA [27]
Tynetec Telehealth
interface unit
Could not be obtained Tynetec [28]
SayPhone 21 Could not be obtained
Table 1 – Proprietary intermediate devices with data display capabilities.
62.3 Evaluation questions
A set of questions were developed to evaluate proprietary intermediate devices.
The questions correspond to four categories.
Setup/configuration: what is the required process to setup the intermediate device?
(Table 2).
Available features: what are the features available on the intermediate device?
(Table 3).
Inputs: how does the intermediate device receive its inputs? (Table 4).
Outputs: what are the outputs produced by the intermediate device? (Table 5).
1 – Setup/configuration
1.1 Are you the only suppliers of the device or can it be purchased from
somewhere else?
1.2 Is the device provided to the patient as fully-functional i.e. plug-and-play or
is specific software required to make the device fully operational in the
system?
1.3 Does the user need to create an online account to establish process?
1.4 Do users need to explicitly configure the device?
1.5 Which environment can the device be used (home only, anywhere)?
1.6 How much does the device cost?
Table 2 – Criteria used to assess proprietary intermediate devices (Setup/configuration).
72 – Available features
2.1 What condition is the device designed to monitor?
2.2 Can the device be customised to several health conditions?
2.3 Is the device for single/multiple users?
2.4 Does the device have voice prompts?
2.5 Does the device have video capabilities?
2.6 Does the device provide reminders?
2.7 Does the device provide instructions of how to carry out the test?
2.8 Is the connection between the point-of-care device and intermediate device
a wired or wireless connection?
2.9 List the type of connections in operation: Bluetooth, Infrared, Wi-Fi etc?
2.10 Is there a progress bar (or something similar) displayed on the device to
show that the user has sent their test results or they are in the process of
being received by the health professional?
2.11 Can the patient send a message to the health professional through the
device?
2.12 Can the patient access historical data through the device?
2.13 Can the patient receive a message from the health professional through the
device?
2.14 Are there authentication requirements before users can proceed with test?
Table 3 – Criteria used to assess proprietary intermediate devices (Available features).
3 – Inputs
3.1 What are the types of point-of-care devices that can be connected?
3.2 Is data transfer automatic from the point-of-care device to the intermediate
device or does the user have to manually enter the data?
3.3 Does the device ask user symptomatic questions?
3.4 What is the mode of interaction between patient and device (touch screen,
button press etc)?
3.5 Does the device confirm the user selection/entry?
Table 4 – Criteria used to assess proprietary intermediate devices (Inputs).
84 – Outputs
4.1 Where is the data from the device transferred to?
4.2 Are alerts provided to the patient on their result before they are sent to a
data repository?
4.3 Do other users within the system receive an alert?
4.4 What is the mode of delivering alerts?
Table 5 – Criteria used to assess proprietary intermediate devices (Outputs).
2.4 Clustering
In order to be able to see how capabilities are clustered in currently available
intermediate devices, the clusters have been presented in the paper in tabulated
form (Tables 6 to 19).
For each cluster table, the horizontal axis shows the device number in the study. The
vertical axis shows the capabilities. Where a capability is present, a tick has been
shown in the table; if absent, it has been shaded in black so that the clustering can
easily be seen visually. Where the data were unobtainable, the corresponding
position in the table has been left blank. Where additional coding of the data were
required, this coding has been shown in a key below the table.
93 Results
This section describes the findings of the analysis of proprietary intermediate devices
based on the questions detailed in Tables 2-5. For each data set, where the data
percentages do not add up to 100%, the remaining data were unobtainable in this
study.
Within each section of the results, there are two parts. The first part concerns
individual capabilities of the devices: how often they are present and what is their
nature. The second concerns how these individual capabilities are clustered on
current devices.
3.1 Availability
93% of intermediate devices are purchasable from a single provider while 7% (device
5) are available from multiple providers (3 suppliers in total).
As shown in Table 6, much less information was available from manufacturers on
devices provided within a system with 79% of data being unavailable. 21% of devices
are sold for use within a system package. Within this group, one device (device 8)
can also be bought off the shelf. Device 5, available from multiple suppliers, is only
sold for use within a system package.
Cost information was generally unavailable from the manufacturers. Manufacturers
indicated that costs varied with quantity and with user requirements.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Single
supplier    
Multiple
suppliers 
Device sold
as part of a
system
package
             
Device can
be bought
off the shelf
           
Cost of
device (£) V    V   1000     V V
Table 6 – Availability of proprietary intermediate devices (Key: V=Variable, depending on request).
3.2 Setup
Devices neither require explicit configuration by the patient, nor establishment of
any on-line account (though information was unavailable in 21% and 29% of cases
respectively).
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3.3 Environments
14% of intermediate devices can be used in both home and hospital, 50% are
exclusively for home use and 36% can be used in any location.
Table 7 shows the clustering of intended device environments. All devices that were
usable outside the home and hospital environment were also designed for use in
that environment.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Home 
Hospital    
Other   
Table 7 – Environments in which proprietary intermediate devices can be used.
3.4 Multiple conditions and point-of-care connection options
All of the intermediate devices evaluated can be customised to manage several
health conditions including: asthma, COPD, diabetes, heart disease and
hypertension. 21% of devices were said to be used for managing unspecified
“chronic conditions”.
Table 8 shows the clustering of conditions by device. The majority of devices are
used for a cluster of four diseases, COPD, diabetes, heart disease and hypertension.
In contrast, asthma is much less well served.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Can be customised
to several health
conditions

Asthma    
COPD    
Diabetes    
Heart disease     
Hypertension    
Unspecified
chronic condition   
Table 8 – Chronic conditions managed by proprietary intermediate devices. (Where the chronic
condition is shown as unspecified, this means that the organization did not describe the condition).
93% of intermediate devices evaluated allow multiple point-of-care devices to be
connected to them. The remaining 7% of intermediate devices obtain their data from
another intermediate device. Point-of-care devices include: glucometers, weighing
11
scales, blood pressure (BP) monitors, pulse oximeters, spirometers and peak flow
meters.
Table 9 shows the different types of point-of-care devices providing inputs to
intermediate devices. The most popular were BP monitor, weighing scale,
glucometer and pulse oximeter. The less popular ones were peak flow meter and
spirometer. The coagulometer and urine analyser were least represented.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
BP monitor   
Weighing scale   
Glucometer  
Pulse oximeter   
Peak flow meter   
Spirometer  
Coagulometer 
Urine analyser 
Table 9 – Types of point-of-care devices providing inputs for proprietary intermediate devices.
3.5 Multiple Users
36% of intermediate devices are designed for the use of multiple users; and 64% by
only a single user (Table 10).
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Device is for
multiple users     
Table 10 – Proprietary intermediate devices designed for multiple users.
3.6 Prompts, Reminders and Confirmations
Voice prompts are available on 64% of devices, 29% do not have this feature.
86% of intermediate devices provide reminders to users, 7% do not.
In cases where users enter data or select an option on the intermediate device, 36%
display a confirmation to the user of the selected option, 21% do not.
64% of intermediate devices ask the user symptomatic questions, whereas 29% do
not.
50% of intermediate devices display a confirmation to the user that their results
have been transferred to the health professional, 21% do not. This confirmation took
the form of a progress bar or a message displayed to the user.
Table 11 shows the clustering of the prompts capabilities of intermediate devices.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Has voice
prompts    
Provides
reminders   
Asks questions     
Confirmation of
the user
selection/ entry
         
Confirmation of
transmission of
results
        
Table 11 – Prompts available on proprietary intermediate devices.
3.7 Alerts
Alerts are provided directly to patients in 29% of intermediate devices (Table 12);
while 64% of devices do not provide alerts to patients. In each case this is in the form
of messages displayed on the intermediate device informing the user that their
result is not within the expected target range.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Alerts on results to
patient before they
are sent to a data
repository
  
Table 12 – Alerts to patients on proprietary intermediate devices.
3.8 Advice, and Communication with the Health professional
57% of intermediate devices provide instructions to the user as to how to carry out a
particular test, 21% do not. In one device (device 5), training videos are provided for
the user.
No device was found to have the capability for patients to send additional messages
to their doctor (though information was unavailable for 29% of cases).
One device (device 12) allows an alarm call to be made to the doctor.
Health professionals are alerted when the patients’ results are outside specified
thresholds. (However, none of these alerts are through the intermediate device.)
29% of intermediate devices enable patients to receive messages from the health
professionals compared with 42% that do not have this feature. In one of the devices
(device 5), a 2-way video call can be organised by the health professional to discuss
issues with the patients. Table 13 shows the device capabilities for advice and
communication.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Provides
instructions of how
to carry out test
     
Has video
capabilities   
Patient can send a
message to the
health professional
  
Patient can receive
a message from
the health
professional
      
Table 13 – Advice provided to users on proprietary intermediate devices.
3.9 Historical data
Patients can access historical data on the device in 36% of intermediate devices
(devices 1, 5, 6, 8, 13) compared with 43% that do not provide this feature.
3.10 Authentication
29% of intermediate devices (devices 1, 5, 8, 13) require authentication by the users,
although this feature requires activation; 50% do not require this.
3.11 Automatic or manual results input
Results of point-of-care tests are automatically transferred from the point-of-care
device to the intermediate devices in 50% of cases. Results are manually entered in
7% of devices. In 29% of devices, results transfer is both automatic and manual.
Table 14Error! Reference source not found. shows the clustering of results transfer
based on mode of input.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Manual data entry
into the device     
Automated data
entry into the
device
  
Table 14 – Automatic or manual results input for proprietary intermediate devices.
3.12 Device Inputs
The inputs for the intermediate devices are either data from point-of-care devices
and/or responses to questionnaires to help assess the symptoms of the patient. 79%
of intermediate devices allow patients to interact with them through buttons, 14%
had a touch screen interface.
Table 15Error! Reference source not found. shows the availability of these features.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Buttons
available for
patient to
interact with
the device
    
Touch screen
available for
patient to
interact with
the device
  
Table 15 – Proprietary intermediate device inputs.
3.13 Information transfer technology
To transfer results to the intermediate device from a point-of-care device, 64% of
devices provide both wired and wireless connections, 21% provide only a wireless
connection. The wireless connections include: Bluetooth, GPRS (General Packet
Radio Service), infrared, radio, GSM (Global System for Mobile Communications),
M2M (Mobile to mobile) Cellular GPS and Wi-Fi. The wired connections are through
USB or serial cables.
Table 16 shows the details of the wired connections from the point-of-care device to
intermediate device with the serial port being the most popular.
Table 17shows the details of the wireless connections from the point-of-care device
to the intermediate device, with Bluetooth being the most widely used.
Table 18 shows the information transfer technology in operation between the
devices and other components of telehealth systems. As can be seen, few providers
made this information available. There is no pattern in the types of information
transfer technology used, although GPRS was used by three devices (2, 8, and 9).
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Wired connection to
point-of-care device      
Serial Port
connections    
USB    
Table 16 – Wired information transfer technology between point-of-care devices and proprietary
intermediate devices.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Wireless
connection to
point-of-care
device
     
Bluetooth     
Infra red  
Radio  
Table 17 – Wireless information transfer technology between point-of-care devices and proprietary
intermediate devices.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
GPRS   
GPS 
GSM 
M2M
Cellular 
POTS  
Wi-Fi 
3G 
Broadband 
Dialup
Modem 
Table 18 – Information transfer technology between proprietary intermediate devices and other
components of telehealth systems.
3.14 Data transfer destination.
Results and responses to the questions are transferred to: a software application
(29%) a secure server (57%) or another intermediate device (7%).
Table 19 shows the breakdown by device.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Data is transferred
to a data server    
Data is transferred
to a software
application
 
Data is transferred
to an intermediate
device
 
Table 19 – Data transfer destination for intermediate devices
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4 Discussion
In this section, the key capabilities and their variance on current proprietary
intermediate devices are summarised. Capabilities of proprietary devices are then
considered based on actor-centric perspectives, i.e. those of the patient, health
professional and payer and system provider. It should be noted that a caregiver
perspective is not given, as no interactions of the devices with caregivers were
found.
4.1 Key capabilities of current proprietary intermediate devices
Three main types of capability were identified from the current analysis.
Firstly: to display information to patients. These are reminders, instructions of how
to conduct tests, symptomatic questions and confirmation of their entry or the
successful transmission of results to another entity. Most proprietary devices
provided reminders and asked the patient questions. Just over half of proprietary
devices showed users how to do their test. Half of proprietary devices showed a
confirmation of results transmission, while few confirmed the user entry.
Secondly: to act as a channel which receives results, automatically from point-of-care
devices or manually via data entry by the patient. Half of devices allowed automatic
input of results, while few allowed manual results entry.
Thirdly: to act as a channel for the forwarding of results and questionnaire responses
to another entity. This may be another intermediate device, external server or
software application. Most proprietary devices transferred results to an external
server.
4.2 Provider perspective
By definition all the devices evaluated in this study were for use in the home. In a
study by Hopp et al., showing the management of diabetes, the devices were only
used within the home environment, however, providers consider multiple
environments to be a market, as more than one third of devices were also suitable
for hospital use [29].
Devices are clearly provider-specific, with only a single device being available from
multiple suppliers. From the limited information available, providers appear keen on
selling a whole system package; only one device is available off the shelf. The state-
of-the-art is therefore that intermediate devices are usually part of closed
proprietary systems.
All of the intermediate devices evaluated can be customised to manage several
health conditions with the majority of devices usable for a cluster of four diseases:
COPD, diabetes, heart disease and hypertension. Hence, nearly all intermediate
devices are designed for connection to more than one point-of-care device. Point-of-
care devices that can be connected include: glucometers, weighing scales, blood
pressure (BP) monitors, pulse oximeters, spirometers and peak flow meters.
This requirement for point-of-care device connectivity leads to information being
widely available from suppliers on information technology for data transfer from
point-of-care device to intermediate device. Nearly all intermediate devices allow
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transfer using both wired and wireless media. In contrast little data is available as to
how the intermediate device connects to rest of the proprietary system.
Interestingly, the multiple connectivity features of intermediate devices, for use to
connect with point-of-care devices, contrast with current point-of-care devices.
Results from a recent study focussing on glucometers showed that only 51% allowed
the data to be transferred. Of these, the majority (90%) used a USB cable, while 10%
used infra-red connection [30]. None used any other wireless technology.
Providers seem divided as to whether single-user or multiple-user intermediate
devices will gain them market share, with only a third of devices being multi-user
capable. Aside from the opportunity to sell more devices, if each device is only for a
single user, providers may consider that this device limitation reduces requirements
for setup and authentication and helps with data security for the patient.
Providers also appear to be currently divided as to the necessity of either voice or
video technology. Voice prompts were present on over half the intermediate
devices, but video technology was available on only one. The case for the utility of
video technology in intermediate devices seems yet to be made.
In contrast, providers are essentially unanimous in device designs which exclude the
initiation of direct communication with a health professional by the patient.
4.3 Patient perspective
Providers appear keen to minimise the information technology knowledge required
of the patient. For the patient this translates to simple setup and authentication
procedures (few devices had any authentication) and automatic data transfer from
the point-of-care device to the intermediate device. Perhaps this is also a reason why
only a third of devices allow patients access to historical data.
Less than a third of devices enable patients to receive messages from the health
professionals with one device allowing a two-way video call initiated by the health
professional.
With regards to device interaction with patients, nearly all devices provide reminders
to patients; over two thirds are capable of quizzing patients about their symptoms.
The majority of devices also provided test instructions. In contrast, the figure for
point-of-care devices (glucometers) for reminders is 19% [30]. This difference
indicates where intermediate devices can bring benefits in patient independence
and compliance above those available from the current generation of point of care
devices.
In contrast, few intermediate devices are designed to provide alerts, for example
following an unexpected result. An anecdotal reason, given by some suppliers, is to
avoid raising false alarms. However, this compares with, again taking glucometers as
examples of point of care devices, to 77% percent that do provide alerts [30].
Certain chronic diseases are risk factors for others, for example, diabetes for
cardiovascular disease, cerebrovascular disease and renal disease [31]. Therefore, it
is a clear benefit from the patient perspective that one intermediate device can
potentially be used with several chronic conditions.
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4.4 Health professional perspective
Unlike for the case of the patient, intermediate devices have little direct contact with
the health professional: the health professional sees aspects of the system rather
than the intermediate device.
The main role of health professionals in relation to the intermediate device is that of
selecting the types of questionnaires that will be used to regularly assess the
patient’s health. This role of health professionals is echoed by Hopp et al., where
questions are specifically configured for patients [29]. Hopp et al., added that health
professionals trained patients in how to use the device to collate their responses
[29]. The aspect of training patients was not investigated in this paper.
4.5 Payer Perspective
The detail of cost of devices was generally unavailable and system providers
indicated the variability of the cost of systems is based on user requirements. Since
devices are provided as part of a telehealth solution it is usually the cost of the
system that the payer sees.
Whilst providers see multiple chronic disease capabilities as a selling point,
anecdotal evidence from one provider indicates that payers are initially interested in
buying provision for a single chronic disease.
4.6 Limitations
In order to predict the directions of future development of proprietary devices, an
extensive survey would need to be carried out to ascertain the expectations of the
actors as to the additional features they need.
There is very limited data and analysis available in the literature on proprietary
intermediate devices. Hence it is difficult to compare and contrast the data and
analysis of this paper with the work of other researchers.
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5 Conclusions
Proprietary intermediate telehealth devices are those which are specifically designed
as connectors between the entities of telehealth systems.
In this paper their capabilities have been analysed in current telehealth systems for
the management of chronic diseases.
From the perspective of the different actors concerned with telehealth systems the
following can be concluded:
Provider perspective: Intermediate devices are usually part of closed proprietary
systems, i.e. they are provider-specific and normally sold as part of a whole system
package. Providers produce disease-customisable devices, capable of connection to
more than one point-of-care device via wired and multiple wireless media; their
connectivity is considerably ahead of the current generation of point-of-care devices.
In contrast little data is available from providers on how the intermediate device
connects to rest of the proprietary system. Providers currently design the majority of
devices for a single-user.
Patient perspective: Simple setup and authentication procedures (few devices had
any authentication) and automatic data transfer from the point-of-care device to the
intermediate device seem key aspects of device design for patients. The majority of
devices provide reminders to patients, quiz patients about their symptoms and
provide test instructions; this contrasts with current point-of-care devices. However,
few intermediate devices are designed to provide alerts, again in contrast to point-
of-care devices. For the patient there is a clear benefit that one intermediate device
can potentially be used with several chronic conditions.
Health Professional perspective: Proprietary intermediate devices have little direct
interaction with the health professional: their current main role is restricted to
selecting the types of questionnaires that will be used to assess the patient’s health.
Payer perspective: The details of costs of devices were generally unavailable and
system providers indicated the variability of the cost of systems is based on user
requirements. Since devices are provided as part of a telehealth solution it is usually
the cost of the system that the payer sees.
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